Full Text:   <1407>

Summary:  <1391>

CLC number: R-052

On-line Access: 2019-01-07

Received: 2018-08-07

Revision Accepted: 2018-12-26

Crosschecked: 2018-12-29

Cited: 0

Clicked: 2126

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Zhi Chen

https://orcid.org/0000-0002-0848-1502

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2019 Vol.20 No.1 P.23-31

http://doi.org/10.1631/jzus.B1800421


Ethical considerations of cellular immunotherapy for cancer


Author(s):  Sang-sang Ren, Jing-wen Deng, Meng Hong, Yan-li Ren, Hai-jing Fu, Yan-ning Liu, Zhi Chen

Affiliation(s):  Health Policy and Hospital Management Research Center, Department of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China; more

Corresponding email(s):   liuyanning@zju.edu.cn, chenzhi@zju.edu.cn

Key Words:  Cancer, Cellular immunotherapy, Ethical issue


Sang-sang Ren, Jing-wen Deng, Meng Hong, Yan-li Ren, Hai-jing Fu, Yan-ning Liu, Zhi Chen. Ethical considerations of cellular immunotherapy for cancer[J]. Journal of Zhejiang University Science B, 2019, 20(1): 23-31.

@article{title="Ethical considerations of cellular immunotherapy for cancer",
author="Sang-sang Ren, Jing-wen Deng, Meng Hong, Yan-li Ren, Hai-jing Fu, Yan-ning Liu, Zhi Chen",
journal="Journal of Zhejiang University Science B",
volume="20",
number="1",
pages="23-31",
year="2019",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1800421"
}

%0 Journal Article
%T Ethical considerations of cellular immunotherapy for cancer
%A Sang-sang Ren
%A Jing-wen Deng
%A Meng Hong
%A Yan-li Ren
%A Hai-jing Fu
%A Yan-ning Liu
%A Zhi Chen
%J Journal of Zhejiang University SCIENCE B
%V 20
%N 1
%P 23-31
%@ 1673-1581
%D 2019
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1800421

TY - JOUR
T1 - Ethical considerations of cellular immunotherapy for cancer
A1 - Sang-sang Ren
A1 - Jing-wen Deng
A1 - Meng Hong
A1 - Yan-li Ren
A1 - Hai-jing Fu
A1 - Yan-ning Liu
A1 - Zhi Chen
J0 - Journal of Zhejiang University Science B
VL - 20
IS - 1
SP - 23
EP - 31
%@ 1673-1581
Y1 - 2019
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1800421


Abstract: 
With the rapid development of immunology, molecular biology, and associated technologies such as next-generation sequencing, cellular immunotherapy has recently become the fourth major cancer treatment. Immunotherapies based on T cells, natural killer cells, and dendritic cells play key roles in cancer immunotherapy. However, their application in clinical practice raises several ethical issues. Thus, studies should focus on proper adherence to basic ethical principles that can effectively guide and solve related clinical problems in the course of treatment, improve treatment effects, and protect the rights and interests of patients. In this review, we discuss cellular immunotherapy-related ethical issues and highlight the ethical practices and current status of cellular immunotherapy in China. These considerations may supplement existing ethical standards in cancer immunotherapy.

肿瘤细胞免疫治疗相关伦理学探讨

概要:本文旨在对细胞免疫治疗相关的伦理学问题进行探讨,并通过分析我国细胞免疫治疗相关伦理学实践及现状,为规范我国肿瘤细胞免疫治疗的伦理标准提供参考.随着免疫学、分子生物学等学科的飞速发展和高通量测序等技术的普及,肿瘤免疫治疗已成为第四大肿瘤治疗方法.肿瘤细胞免疫治疗,如各种基于T细胞、自然杀伤(NK)细胞和树突状细胞(DC)的免疫治疗在其中发挥了重要作用.随着临床实践的开展,一些相关的伦理学问题逐渐暴露出来.如何在治疗过程中坚持基本伦理原则,有效指导并解决相关临床问题,提高治疗效果,保护受试者权益,是目前亟需研究的重要课题.本文对与之相关的伦理学问题进行探讨,并通过分析我国细胞免疫治疗相关伦理学实践及现状,以期为规范我国肿瘤细胞免疫治疗的伦理标准提供参考.
关键词:肿瘤;细胞免疫治疗;伦理问题

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Adachi K, Kano Y, Nagai T, et al., 2018. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol, 36(4):346-351.

[2]Anderson AC, Joller N, Kuchroo VK, 2016. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity, 44(5):989-1004.

[3]Anguille S, Smits EL, Lion E, et al., 2014. Clinical use of dendritic cells for cancer therapy. Lancet Oncol, 15(7):e257-e267.

[4]Benson DM Jr, Bakan CE, Mishra A, et al., 2010. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood, 116(13):2286-2294.

[5]Cheng M, Chen YY, Xiao WH, et al., 2013. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol, 10(3):230-252.

[6]Childs RW, Carlsten M, 2015. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov, 14(7):487-498.

[7]Couzin-Frankel J, 2013. Cancer immunotherapy. Science, 342(6165):1432-1433.

[8]Fukuda K, Funakoshi T, Sakurai T, et al., 2017. Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma. Melanoma Res, 27(4):326-334.

[9]Glienke W, Esser R, Priesner C, et al., 2015. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol, 6:21.

[10]Gross G, Waks T, Eshhar Z, 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA, 86(24):10024-10028.

[11]Gubin MM, Artyomov MN, Mardis ER, et al., 2015. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest, 125(9):3413-3421.

[12]Hansen M, Hjortø GM, Donia M, et al., 2013. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine, 31(4):639-646.

[13]Helmby H, 2009. Gastrointestinal nematode infection exacerbates malaria-induced liver pathology. J Immunol, 182(9):5663-5671.

[14]Hermanson DL, Kaufman DS, 2015. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol, 6:195.

[15]Hsu FJ, Benike C, Fagnoni F, et al., 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med, 2(1):52-58.

[16]Jackson HJ, Rafiq S, Brentjens RJ, 2016. Driving CAR T-cells forward. Nat Rev Clin Oncol, 13(6):370-383.

[17]Kochenderfer JN, Dudley ME, Kassim SH, et al., 2015. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol, 33(6):540-549.

[18]Mao QX, Li LF, Zhang CJ, et al., 2015. Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer. Pak J Pharm Sci, 28(S3):1055-1058.

[19]Maude SL, Frey N, Shaw PA, et al., 2014. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 371(16):1507-1517.

[20]Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al., 2005. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105(8):3051-3057.

[21]Morgan RA, Dudley ME, Wunderlich JR, et al., 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314(5796):126-129.

[22]Muul LM, Spiess PJ, Director EP, et al., 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol, 138(3):989-995.

[23]Robinson MW, Harmon C, O'Farrelly C, 2016. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol, 13(3):267-276.

[24]Rosenberg SA, Packard BS, Aebersold PM, et al., 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med, 319(25):1676-1680.

[25]Ruggeri L, Capanni M, Urbani E, et al., 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295(5562):2097-2100.

[26]Ruggeri L, Urbani E, André P, et al., 2016. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica, 101(5):626-633.

[27]Shimodaira S, Sano K, Hirabayashi K, et al., 2015. Dendritic cell-based adjuvant vaccination targeting Wilms’ tumor 1 in patients with advanced colorectal Cancer. Vaccines (Basel), 3(4):1004-1018.

[28]Sims RB, 2012. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine, 30(29):4394-4397.

[29]Strønen E, Toebes M, Kelderman S, et al., 2016. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science, 352(6291):1337-1341.

[30]Su J, Han YH, 2016. Ethical reflection on “Wei Zexi incident”. J Kunming Univ Sci Technol, 16(4):17-21 (in Chinese).

[31]Verdegaal EME, de Miranda NFCC, Visser M, et al., 2016. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature, 536(7614):91-95.

[32]World Medical Association, 2013. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, 310(20):2191-2194. http://doi.org/10.1001/jama.2013.281053

[33]Yang Y, Lu Q, Liu YF, et al., 2016. Investigating the gray zone in ethical review of medical new technology: innovative treatment vs. experimental care. Med Philos, 37(8):94-97 (in Chinese).

[34]Ying KM, Ding Y, Chen YQ, et al., 2012. The ethical principles of clinical studies of DC-CIK cellular biotherapy technology. Hosp Admin J Chin PLA, 19(6):513-514 (in Chinese).

[35]Yu H, Qu P, Liu LB, 2005. Ethical issues and progress in clinical study of dendritic cell tumor vaccine. Chin Med Ethics, 40(4):60-62 (in Chinese).

[36]Zhang CC, Oberoi P, Oelsner S, et al., 2017. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol, 8:533.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE